On January 19, 2023 SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported that it will host a virtual key opinion leader event to discuss the current treatment landscape for patients suffering from acute myeloid leukemia (AML) and the potential for galinpepimut-S (GPS) as a treatment solution (Press release, Sellas Life Sciences, JAN 19, 2023, View Source [SID1234626353]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webinar event will feature Omer Jamy, MD who is principal investigator of the Phase 3 REGAL study at the University of Alabama at Birmingham (UAB), one of the highest enrolling REGAL sites. He is currently Assistant Professor of Medicine at UAB in the Division of Hematology and Oncology and Associate Scientist, Experimental Therapeutics at the O’Neal Comprehensive Cancer Center. Dr. Jamy is principal investigator on several clinical trials in addition to REGAL, focusing on AML, chronic myelogenous leukemia, and allogeneic stem cell transplantation. Dr. Jamy completed his internal medicine residency at the University of Tennessee in Memphis followed by fellowship training at UAB in hematology/oncology, bone marrow transplantation and cellular therapy.
The SELLAS management team will provide a corporate update on GPS, their lead pipeline candidate, which is currently being evaluated in a Phase 3 registrational clinical trial in AML patients who have achieved complete remission following second-line salvage therapy. GPS targets malignancies and tumors characterized by an overexpression of the WT1 antigen, one of the most widely expressed cancer antigens in multiple malignancies.